Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 21:15:63-71.
doi: 10.2147/DHPS.S348501. eCollection 2023.

The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection - A Systematic Review

Maja Johanne Søndergaard Knudsen #  1 , Ingrid Maria Cecilia Rubin #  1 , Andreas Munk Petersen  1   2   3
Affiliations
Review

The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection - A Systematic Review

Maja Johanne Søndergaard Knudsen et al. Drug Healthc Patient Saf. .

Abstract

Introduction: The aim of this systematic review of randomized clinical trials (RCTs) was to examine the efficacy, safety, and tolerability of vancomycin for treatment of recurrent Clostridioides difficile infection (rCDI).

Methods: The PubMed database was searched from inception to August 23, 2022. An initial screening was performed followed by a full-text evaluation of the papers. Inclusion criteria were RCTs investigating vancomycin for treatment of rCDI.

Results: A total of six studies and 269 patients were included in the review. Three studies used a fixed dose regimen of vancomycin, one study used pulse regimen, one study used a taper-and-pulse regimen, and one study used a taper-and-pulse regimen for the participants with two or more recurrences. The resolution of infection varied from 19% to 58.3% in five of six studies reporting this as an outcome. Four out of six studies reported new episodes of rCDI as an intervention outcome, in those studies 50-63% of participants experienced rCDI. Regarding the safety and tolerability of vancomycin treatment for rCDI, one study described several adverse events regarding gastrointestinal discomfort along with fatigue and skin rash. There were no records of serious adverse events in the included studies.

Conclusion: While oral vancomycin is mostly safe and well tolerated in the RCTs reviewed here, the efficacy for treating rCDI varies greatly from 19-58.3%, and 50-63% of participants experienced new episodes of rCDI.

Keywords: Clostridioides difficile; diarrhoea; infection; recurrent; vancomycin.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Shows the flow chart of inclusion and exclusion of records.
Figure 2
Figure 2
Shows the risk of bias assessment on criteria 1–14 (refer to Supplementary Document 2). For each study, criteria with low risk of bias are colored green, high risk of bias are colored red, and unclear risk of bias are colored yellow.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent clostridium difficile disease: use of high‐dose vancomycin combined with saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–1017. doi:10.1086/318130 - DOI - PubMed
    1. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection. Gastroenterology. 2019;156(5):1324–1332.e3. doi:10.1053/j.gastro.2018.12.019 - DOI - PubMed
    1. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–843. doi:10.1111/apt.13144 - DOI - PubMed
    1. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73. doi:10.1016/S0140-6736(10)61266-4 - DOI - PubMed
    1. Garcia PG, Chebli LA, da Rocha Ribeiro TC, et al. Impact of superimposed Clostridium difficile infection in Crohn’s or ulcerative colitis flares in the outpatient setting. Int J Colorectal Dis. 2018;33(9):1285–1294. doi:10.1007/s00384-018-3105-8 - DOI - PubMed